Asset
Pegunigalsidase Alfa
Protalix BioTherapeutics Inc. (DE) Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01678898 | phase1_2 | completed | 2012-10-01 | 2016-03-06 | Protalix | Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients |
| NCT01981720 | phase1_2 | completed | 2014-01-16 | 2020-08-26 | Protalix | Extension Study of PRX-102 for up to 60 Months |
| NCT03018730 | phase3 | completed | 2017-05-17 | 2019-12-17 | Protalix | Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa) |
| NCT02795676 | phase3 | completed | 2016-06-01 | 2021-10-01 | Protalix | Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function |
| NCT02921620 | phase3 | withdrawn | 2017-07-01 | 2018-07-01 | Protalix | Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease |
FDA applications (0)
This company has no applications containing this asset.